GlassScriptPhysician profile
Jungman M Suh
NPI 1003076886
$1,983.91
in general payments reported to CMS, 2019-2025
24 companies · $414 in 2025
The $414 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90.76 · 2020: $216 · 2021: $538 · 2022: $241 · 2023: $80.37 · 2024: $404 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $898.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $403.81 | 2021-2025 | |
| Adamas Pharmaceuticals, INC. | $314.19 | 2020-2021 | |
| Eisai INC. | $278.18 | 2023-2025 | |
| Medtronic, INC. | $139.67 | 2024-2025 | Percept PC Brainsense |
| Biogen, INC. | $111.67 | 2021 | |
| Ucb, INC. | $110.97 | 2023-2024 | Nayzilam |
| Corium, LLC | $87.05 | 2022-2024 | Azstarys |
| Allergan, INC. | $75.41 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $74.00 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $71.03 | 2020 | |
| Neurelis, INC. | $39.59 | 2020 | |
| Acorda Therapeutics, INC | $34.41 | 2019 | |
| Lilly USA, LLC | $34.31 | 2025 | Kisunla |
| Neuronetics, INC. | $27.26 | 2022 | |
| Argenx US, INC. | $25.00 | 2024 | Vyvgart Hytrulo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $22.43 | 2019 | |
| Cepheid | $21.58 | 2025 | Genexpert |
| Amylyx Pharmaceuticals, INC. | $17.43 | 2024 | Relyvrio |
| Akcea Therapeutics, INC. | $17.03 | 2019 | |
| Acadia Pharmaceuticals INC | $16.89 | 2019 | |
| Genentech USA, INC. | $16.86 | 2023 | Evrysdi |
| Ge Healthcare | $16.66 | 2021 | |
| Avion Pharmaceuticals | $14.42 | 2022 | |
| Supernus Pharmaceuticals, INC. | $14.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jungman Suh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.